Gail Berman

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

Richard C. Becker, David J. Moliterno, Lisa K. Jennings et al. · The Lancet · 2009 · 297 citations

Medicine, Cardiology, Pharmacotherapy +10

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

David A. Morrow, Benjamin M. Scirica, Keith A.A. Fox et al. · American Heart Journal · 2009 · 172 citations

Medicine, Cardiology, Pharmacotherapy +14

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

C. Michael Gibson, John J.P. Kastelein, Adam Phillips et al. · American Heart Journal · 2020 · 85 citations · Full text

Medicine, Cardiology, Pharmacology +17

Prevalence of multivalvular regurgitation in athletes

Pamela S. Douglas, Gail Berman, Mary L. OʼToole et al. · The American Journal of Cardiology · 1989 · 53 citations

Medicine, Cardiology, Sports Medicine +9

Effects of sample volume location, imaging view, heart rate and age on tricuspid velocimetry in normal subjects

Gail Berman, Nathaniel Reichek, D Brownson et al. · The American Journal of Cardiology · 1990 · 37 citations

Veterinary Medicine, Cardiology, Physiology +13